Faculty Profiles - KATSUNO, Masahisa

Papers - KATSUNO, Masahisa

Division display 481 - 488 of about 488 ／ All the affair displays >>

Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70. Reviewed

Suzuki S, Maruyama S, Sato W, Morita Y, Sato F, Miki Y, Kato S, Katsuno M, Sobue G, Yuzawa Y, Matsuo S.

Kidney Int Vol. 67 page： 2210-2220 2005

Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Reviewed

Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, Mori K, Koike H, Hattori N, Arimura K, Nakagawa M, Yoshikawa H, Hayasaka K, Onodera O, Baba M, Yasuda H, Saito T, Nakazato M, Nakashima K, Kira J, Kaji R, Oka N, Sobue G.

Neurology Vol. 64 page： 1471-1475 2005

Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Reviewed

Jiang YM, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, Terao S, Takeuchi H, Ishigaki S, Katsuno M, Adachi H, Niwa J, Tanaka F, Doyu M, Yoshida M, Hashizume Y, Sobue G.

Ann Neurol Vol. 57 page： 236-251 2005

Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. Reviewed

Watanabe H, Fukatsu H, Katsuno M, Sugiura M, Hamada K, Okada Y, Hirayama M, Ishigaki T, Sobue G.

J Neurol Neurosurg Psychiatry Vol. 75 page： 103-109 2004

Polyglutamine diminishes VEGF; passage to motor neuron death? Invited Reviewed

Katsuno M, Sobue G.

Neuron Vol. 41 page： 677-679 2004

Sweet relief for Huntington disease. Invited Reviewed

Katsuno M, Adachi H, Sobue G.

Nat Med Vol. 10 page： 123-124 2004

Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives. Invited Reviewed

Katsuno M, Adachi H, Tanaka F, Sobue G.

J Mol Med Vol. 82 page： 298-307 2004

Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Reviewed

Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G.

Hum Mol Genet Vol. 13 page： 1183-92 2004

Language：English Publishing type：Research paper (scientific journal)

Spinal and bulbar muscular atrophy (SBMA) is an inherited motor neuron disease caused by the expansion of a polyglutamine (polyQ) tract within the androgen receptor. Unifying mechanisms have been implicated in the pathogenesis of polyQ-dependent neurodegenerative diseases including SBMA, Huntington disease and spinocerebellar ataxias. It has been suggested that mutant protein containing polyQ inhibits histone acetyltransferase activity, resulting in transcriptional dysfunction and subsequent neuronal dysfunction. Histone deacetylase (HDAC) inhibitors alleviate neurological phenotypes in fly and mouse models of polyQ disease, although the therapeutic effect is limited by the toxicity of these compounds. We studied the therapeutic effects of sodium butyrate (SB), an HDAC inhibitor, in a transgenic mouse model of SBMA. Oral administration of SB ameliorated neurological phenotypes as well as increased acetylation of nuclear histone in neural tissues. These therapeutic effects, however, were seen only within a narrow range of SB dosage. Our results indicate that SB is a possible therapeutic agent for SBMA and other polyQ diseases, although an appropriate dose should be determined for clinical application.

　 PREV - NEXT 　

<KATSUNO, Masahisa>

Papers - KATSUNO, Masahisa